数据日期 2026-10-29 · 生成时间 2026-10-29 06:03
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
研究问题
To evaluate whether Hematopoietic Cell Transplantation Frailty Scale (HCT-FS)-defined frailty predicts overall survival (OS), nonrelapse mortality (NRM), and relapse across diverse hematologic diagnoses undergoing allogeneic hematopoietic cell transplantation (alloHCT), including nonmalignant disorders.
方法
We conducted a multicenter retrospective cohort study of 992 adults undergoing alloHCT at 16 centers in Canada and Spain (2018-2023).；HCT-FS-defined frailty is associated with OS and NRM but not relapse in this multicenter alloHCT cohort.
核心结论
Frailty was assessed at consultation using the HCT-FS (fit, prefrail, frail).；OS was estimated by Kaplan-Meier, competing-risks methods by cumulative incidence.；Multivariable models assessed associations with OS and NRM.；Frailty was assessed across six diagnostic categories, including nonmalignant disorders (4.8%). ‖ 结论：HCT-FS-defined frailty is associated with OS and NRM but not relapse in this multicenter alloHCT cohort.
局限
未能获取全文，具体设计细节、失访与统计学处理无法核验。
对本项目的价值
★★☆☆☆ 衰弱/肌少症是少有的已有监管认可终点的老年综合征，是临床转化的最短路径。
原文题录
- 英文标题：HCT-FS-Defined Frailty Is Associated With Lower Survival Across Diverse Hematologic Diagnoses After Allogeneic Transplantation.
- 期刊与标识：Eur J Haematol · PMID 42949150 · DOI 10.1111/ejh.70344**
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」（SOP §4.2 摘要级）撰写，依据期刊公开摘要与 PubMed 元数据；付费墙全文未获取之处已标注「待补全文」，未做任何数值推算补全。